Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
surzebiclimab (BGB-A425)
i
Other names:
BGB-A425
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
BeiGene
Drug class:
TIM-3 inhibitor
Related drugs:
‹
LB1410 (0)
LY3321367 (0)
LY3415244 (0)
NB002 (0)
S95018 (0)
SHR-1702 (0)
TQB2618 (0)
RG7769 (0)
AZD7789 (0)
INCAGN2390 (0)
LB1410 (0)
LY3321367 (0)
LY3415244 (0)
NB002 (0)
S95018 (0)
SHR-1702 (0)
TQB2618 (0)
RG7769 (0)
AZD7789 (0)
INCAGN2390 (0)
›
Associations
News
Trials
Filter by
Latest
5ms
BGB-HNSCC-201: Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=160, Recruiting, BeiGene
5 months ago
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab) • LBL-007 • surzebiclimab (BGB-A425)
10ms
Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=160, Recruiting, BeiGene | Not yet recruiting --> Recruiting
10 months ago
Enrollment open • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab) • LBL-007 • surzebiclimab (BGB-A425)
11ms
Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
P2, N=160, Not yet recruiting, BeiGene
11 months ago
New P2 trial • Combination therapy • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab) • LBL-007 • surzebiclimab (BGB-A425)
over1year
BGB-900-102: Study of BGB-A425 and LBL-007 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=358, Recruiting, BeiGene | N=162 --> 358 | Trial completion date: Jan 2024 --> Dec 2027 | Trial primary completion date: Jul 2023 --> Mar 2026
over 1 year ago
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab) • LBL-007 • surzebiclimab (BGB-A425)
over2years
Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=162, Recruiting, BeiGene | Trial completion date: Sep 2023 --> Jan 2024 | Trial primary completion date: Mar 2023 --> Jul 2023
over 2 years ago
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Tevimbra (tislelizumab) • surzebiclimab (BGB-A425)
almost3years
Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=162, Recruiting, BeiGene | Trial completion date: Dec 2021 --> Sep 2023 | Trial primary completion date: Jun 2021 --> Mar 2023
almost 3 years ago
Clinical • Trial completion date • Trial primary completion date • Combination therapy
|
PD-L1 (Programmed death ligand 1)
|
Tevimbra (tislelizumab) • surzebiclimab (BGB-A425)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login